Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
1.
Article in English | MEDLINE | ID: mdl-28424549

ABSTRACT

OBJECTIVES: Clinical practice in chronic obstructive pulmonary disease (COPD) can be influenced by weather variability throughout the year. To explore the hypothesis of seasonal variability in clinical practice, the present study analyzes the results of the 2013-2014 Andalusian COPD audit with regard to changes in clinical practice according to the different seasons. METHODS: The Andalusian COPD audit was a pilot clinical project conducted from October 2013 to September 2014 in outpatient respiratory clinics of hospitals in Andalusia, Spain (8 provinces with more than 8 million inhabitants) with retrospective data gathering. For the present analysis, astronomical seasons in the Northern Hemisphere were used as reference. Bivariate associations between the different COPD guidelines and the clinical practice changes over the seasons were explored by using binomial multivariate logistic regression analysis with age, sex, Charlson comorbidity index, type of hospital, and COPD severity by forced expiratory volume in 1 second as covariates, and were expressed as odds ratio (OR) with 95% confidence intervals (CIs). RESULTS: The Andalusian COPD audit included 621 clinical records from 9 hospitals. After adjusting for covariates, only inhaler device satisfaction evaluation was found to significantly differ according to the seasons with an increase in winter (OR, 3.460; 95% CI, 1.469-8.151), spring (OR, 4.215; 95% CI, 1.814-9.793), and summer (OR, 3.371; 95% CI, 1.391-8.169) compared to that in autumn. The rest of the observed differences were not significant after adjusting for covariates. However, compliance with evaluating inhaler satisfaction was low. CONCLUSION: The various aspects of clinical practice for COPD care were found to be quite homogeneous throughout the year for the variables evaluated. Inhaler satisfaction evaluation, however, presented some significant variation during the year. Inhaler device satisfaction should be evaluated during all clinical visits throughout the year for improved COPD management.


Subject(s)
Bronchodilator Agents/administration & dosage , Lung/drug effects , Process Assessment, Health Care , Pulmonary Disease, Chronic Obstructive/drug therapy , Seasons , Administration, Inhalation , Aged , Chi-Square Distribution , Female , Forced Expiratory Volume , Humans , Logistic Models , Lung/physiopathology , Male , Medical Audit , Middle Aged , Multivariate Analysis , Nebulizers and Vaporizers , Odds Ratio , Patient Satisfaction , Pilot Projects , Pulmonary Disease, Chronic Obstructive/diagnosis , Pulmonary Disease, Chronic Obstructive/epidemiology , Pulmonary Disease, Chronic Obstructive/physiopathology , Quality Indicators, Health Care , Retrospective Studies , Spain/epidemiology , Time Factors , Treatment Outcome
2.
Article in English | MEDLINE | ID: mdl-27330285

ABSTRACT

INTRODUCTION: This study is an analysis of a pilot COPD clinical audit that evaluated adherence to guidelines for patients with COPD in a stable disease phase during a routine visit in specialized secondary care outpatient clinics in order to identify the variables associated with the decision to step-up or step-down pharmacological treatment. METHODS: This study was a pilot clinical audit performed at hospital outpatient respiratory clinics in the region of Andalusia, Spain (eight provinces with over eight million inhabitants), in which 20% of centers in the area (catchment population 3,143,086 inhabitants) were invited to participate. Treatment changes were evaluated in terms of the number of prescribed medications and were classified as step-up, step-down, or no change. Three backward stepwise binominal multivariate logistic regression analyses were conducted to evaluate variables associated with stepping up, stepping down, and inhaled corticosteroids discontinuation. RESULTS: The present analysis evaluated 565 clinical records (91%) of the complete audit. Of those records, 366 (64.8%) cases saw no change in pharmacological treatment, while 99 patients (17.5%) had an increase in the number of drugs, 55 (9.7%) had a decrease in the number of drugs, and 45 (8.0%) noted a change to other medication for a similar therapeutic scheme. Exacerbations were the main factor in stepping up treatment, as were the symptoms themselves. In contrast, rather than symptoms, doctors used forced expiratory volume in 1 second and previous treatment with long-term antibiotics or inhaled corticosteroids as the key determinants to stepping down treatment. CONCLUSION: The majority of doctors did not change the prescription. When changes were made, a number of related factors were noted. Future trials must evaluate whether these therapeutic changes impact clinically relevant outcomes at follow-up.


Subject(s)
Adrenal Cortex Hormones/administration & dosage , Bronchodilator Agents/administration & dosage , Clinical Decision-Making , Lung/drug effects , Practice Patterns, Physicians' , Process Assessment, Health Care , Pulmonary Disease, Chronic Obstructive/drug therapy , Administration, Inhalation , Adrenal Cortex Hormones/adverse effects , Aged , Anti-Bacterial Agents/administration & dosage , Bronchodilator Agents/adverse effects , Disease Progression , Drug Prescriptions , Drug Therapy, Combination , Female , Forced Expiratory Volume , Guideline Adherence , Humans , Logistic Models , Lung/physiopathology , Male , Medical Audit , Middle Aged , Multivariate Analysis , Odds Ratio , Outpatient Clinics, Hospital , Phenotype , Pilot Projects , Practice Guidelines as Topic , Pulmonary Disease, Chronic Obstructive/diagnosis , Pulmonary Disease, Chronic Obstructive/physiopathology , Secondary Care , Treatment Outcome , Vital Capacity
3.
PLoS One ; 11(3): e0151896, 2016.
Article in English | MEDLINE | ID: mdl-26985822

ABSTRACT

OBJECTIVES: Previous clinical audits of COPD have provided relevant information about medical intervention in exacerbation admissions. The present study aims to evaluate adherence to current guidelines in COPD through a clinical audit. METHODS: This is a pilot clinical audit performed in hospital outpatient respiratory clinics in Andalusia, Spain (eight provinces with more than 8 million inhabitants), including 9 centers (20% of the public centers in the area) between 2013 and 2014. Cases with an established diagnosis of COPD based on risk factors, clinical symptoms, and a post-bronchodilator FEV1/FVC ratio of less than 0.70 were deemed eligible. The performance of the outpatient clinics was benchmarked against three guidance documents available at the time of the audit. The appropriateness of the performance was categorized as excellent (>80%), good (60-80%), adequate (40-59%), inadequate (20-39%), and highly inadequate (<20%). RESULTS: During the audit, 621 clinical records were audited. Adherence to the different guidelines presented a considerable variability among the different participating hospitals, with an excellent or good adherence for symptom recording, MRC or CAT use, smoking status evaluation, spirometry, or bronchodilation therapy. The most outstanding areas for improvement were the use of the BODE index, the monitoring of treatments, the determination of alpha1-antitrypsin, the performance of exercise testing, and vaccination recommendations. CONCLUSIONS: The present study reflects the situation of clinical care for COPD patients in specialized secondary care outpatient clinics. Adherence to clinical guidelines shows considerable variability in outpatient clinics managing COPD patients, and some aspects of the clinical care can clearly be improved.


Subject(s)
Ambulatory Care Facilities/standards , Guideline Adherence , Pulmonary Disease, Chronic Obstructive/therapy , Aged , Aged, 80 and over , Clinical Audit , Female , Humans , Male , Middle Aged , Outpatients , Practice Guidelines as Topic , Pulmonary Disease, Chronic Obstructive/physiopathology
4.
PLoS One ; 10(11): e0141856, 2015.
Article in English | MEDLINE | ID: mdl-26544556

ABSTRACT

OBJECTIVES: Previous clinical audits for chronic obstructive pulmonary disease (COPD) have provided valuable information on the clinical care delivered to patients admitted to medical wards because of COPD exacerbations. However, clinical audits of COPD in an outpatient setting are scarce and no methodological guidelines are currently available. Based on our previous experience, herein we describe a clinical audit for COPD patients in specialized outpatient clinics with the overall goal of establishing a potential methodological workflow. METHODS: A pilot clinical audit of COPD patients referred to respiratory outpatient clinics in the region of Andalusia, Spain (over 8 million inhabitants), was performed. The audit took place between October 2013 and September 2014, and 10 centers (20% of all public hospitals) were invited to participate. Cases with an established diagnosis of COPD based on risk factors, clinical symptoms, and a post-bronchodilator FEV1/FVC ratio of less than 0.70 were deemed eligible. The usefulness of formally scheduled regular follow-up visits was assessed. Two different databases (resources and clinical database) were constructed. Assessments were planned over a year divided by 4 three-month periods, with the goal of determining seasonal-related changes. Exacerbations and survival served as the main endpoints. CONCLUSIONS: This paper describes a methodological framework for conducting a clinical audit of COPD patients in an outpatient setting. Results from such audits can guide health information systems development and implementation in real-world settings.


Subject(s)
Ambulatory Care Facilities/standards , Clinical Audit/methods , Pulmonary Disease, Chronic Obstructive , Workflow , Benchmarking , Data Collection , Female , Humans , Internet , Male
5.
Arch. bronconeumol. (Ed. impr.) ; 48(12): 479-481, dic. 2012. ilus
Article in Spanish | IBECS | ID: ibc-107740

ABSTRACT

La linfangioleiomiomatosis (LAM) es una enfermedad rara caracterizada por la proliferación anormal de células musculares lisas inmaduras y una destrucción quística del pulmón, que condiciona el pronóstico de la enfermedad. Los angiomiolipomas renales suelen ser muy frecuentes en esta enfermedad, generalmente de curso asintomático, salvo complicaciones. Ante la ausencia de un tratamiento curativo, las últimas publicaciones reflejan resultados esperanzadores en la terapia molecular para evitar el deterioro funcional y el control del tamaño de los angiomiolipomas. Entre estas terapias destacan los inhibidores del complejo mTOR, sobre todo sirolimus. Presentamos un caso clínico de una paciente diagnosticada de LAM sometida a trasplante pulmonar con reducción del tamaño del angiomiolipoma renal tras el tratamiento con el inhibidor mTOR everolimus(AU)


Lymphangioleiomyomatosis (LAM) is a rare disease characterized by abnormal proliferation of immature smooth muscle cells and cystic lung destruction, which determines the prognosis of the disease. The kidney angiomyolipomas are usually very common in this disease and are usually asymptomatic unless complications arise. In the absence of a curative treatment, recent publications show promising results in molecular therapy to prevent functional decline and to control the size of the angiomyolipomas. These therapies include mTOR complex inhibitors, especially sirolimus. We report a case of a patient diagnosed with LAM who underwent lung transplantation with reduction of renal angiomyolipoma size after treatment with the mTOR inhibitor everolimus(AU)


Subject(s)
Humans , Female , Adult , Angiomyolipoma/drug therapy , Kidney Neoplasms/drug therapy , TOR Serine-Threonine Kinases/antagonists & inhibitors , Lymphangioleiomyomatosis/complications , Angiomyolipoma/complications , Kidney Neoplasms/complications , TOR Serine-Threonine Kinases/pharmacology , Molecular Targeted Therapy , Lung Transplantation
6.
Arch Bronconeumol ; 48(12): 479-81, 2012 Dec.
Article in English, Spanish | MEDLINE | ID: mdl-22444789

ABSTRACT

Lymphangioleiomyomatosis (LAM) is a rare disease characterized by abnormal proliferation of immature smooth muscle cells and cystic lung destruction, which determines the prognosis of the disease. The kidney angiomyolipomas are usually very common in this disease and are usually asymptomatic unless complications arise. In the absence of a curative treatment, recent publications show promising results in molecular therapy to prevent functional decline and to control the size of the angiomyolipomas. These therapies include mTOR complex inhibitors, especially sirolimus. We report a case of a patient diagnosed with LAM who underwent lung transplantation with reduction of renal angiomyolipoma size after treatment with the mTOR inhibitor everolimus.


Subject(s)
Angiomyolipoma/drug therapy , Antineoplastic Agents/therapeutic use , Kidney Neoplasms/drug therapy , Kidney Neoplasms/pathology , Lung Transplantation , Lymphangioleiomyomatosis/surgery , Sirolimus/analogs & derivatives , Adult , Angiomyolipoma/complications , Angiomyolipoma/pathology , Everolimus , Female , Humans , Kidney Neoplasms/complications , Lymphangioleiomyomatosis/complications , Sirolimus/therapeutic use , Tumor Burden
7.
Intern Med ; 51(4): 363-8, 2012.
Article in English | MEDLINE | ID: mdl-22333370

ABSTRACT

OBJECTIVE: To evaluate the impact of oxidative stress and cellular adhesion molecules on ischemic reactive hyperemia (IRH) in patients with OSA. MATERIALS AND METHODS: Consecutive patients treated at a sleep laboratory and whose polysomnography showed an apnea hypopnea index (AHI) ≥5 were included in the study. Patients with acute illness receiving vasoactive medications were excluded. Based on their oxygen desaturation index (ODI), subjects were assigned to the mild-moderate (ODI ≤30) or the severe desaturation group (ODI >30). Then IRH and oxidative stress markers [malondialdehyde (MDA)] and proinflammatory markers (ICAM-1 and P-selectin) were measured. RESULTS: Sixty-eight subjects with OSA were included, 31 in the mild-moderate desaturation group and 37 in the severe group. No differences by age, gender and body mass index were observed. The severe desaturation group showed significantly higher values in the AHI, MDA, ICAM-1 and P-selectin (p<0.005), as well as a worsening of IRH (p=0.001). Only ICAM-1 (p=0.019) and P-selectin (p=0.033) were independently associated with IRH in a multiple-linear regression model. CONCLUSION: Patients with OSA and greater intermittent hypoxia showed worse endothelial function, and higher levels of MDA, ICAM-1 and P-selectin. Nevertheless, ICAM-1 and P-selectin rather than MDA were independently associated with IRH.


Subject(s)
Cell Adhesion Molecules/physiology , Endothelial Cells/physiology , Hyperemia/physiopathology , Oxidative Stress/physiology , Sleep Apnea, Obstructive/physiopathology , Adult , Aged , Atherosclerosis , Biomarkers/blood , Body Mass Index , Cell Adhesion Molecules/blood , Female , Humans , Intercellular Adhesion Molecule-1/blood , Laser-Doppler Flowmetry , Male , Malondialdehyde/blood , Middle Aged , P-Selectin/blood , Polysomnography , Prospective Studies
SELECTION OF CITATIONS
SEARCH DETAIL
...